Digestive Remedies in Brazil

Digestive Remedies in Brazil

  • October 2017 •
  • 19 pages •
  • Report ID: 149927
ANVISA is expected to approve switches of some substances that are globally considered OTC in the short term, maybe at the end of 2017.

This approval should include substances such as omeprazole, classified under proton pump inhibitors, which is still sold through prescription drugs in Brazil. Consequently, sales of digestive remedies should significantly increase in part thanks to this switch during the forecast period. There is great demand amongst Brazilians for proton pump inhibitors that pr...

Euromonitor International’s Digestive Remedies in Brazil report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2012-2016, allowing you to identify the sectors driving growth. Forecasts to 2021 illustrate how the market is set to change.

Product coverage:
Diarrhoeal Remedies, IBS Treatments, Indigestion and Heartburn Remedies, Laxatives, Motion Sickness Remedies, Paediatric Digestive Remedies.

Data coverage:
market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Digestive Remedies market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.

Country=Brazil Industry=OTC ParentIndustry=LifeSciences Date=201710 Topic=Demand Publisher=EuromonitorInternational Price=1000